How generic prices for Alpelisib compare

Alpelisib (Alpelisib) - Piqray is the first PI3Kα inhibitor approved for the treatment of breast cancer. Since it was launched in the United States in 2007, it has attracted widespread attention due to its outstanding efficacy and precise target. However, the price of its original drugs is relatively high, and the economic burden of long-term use has become a core issue for patients. In recent years, as patent protection gradually expires, some overseas pharmaceutical companies have launched generic versions, which has significantly reduced drug prices and provided new affordable options for more patients.

Currently, the original drug of Apelvis is produced by Novartis, and the retail price in overseas markets is relatively high. Each box in the United States is about RMB ranging from RMB 30,000 to RMB 50,000. Since it has not yet been approved for marketing in mainland China, there is no official domestic selling price and medical insurance price. However, pharmaceutical companies in Laos and other countries have developed generic versions of Apelvis. For example, the 150mg version produced by Lucius Pharmaceutical Factory in Laos has a market price of about 2,000 yuan per box of 28 tablets, which is about ten times cheaper than the original drug.

From a pharmacological perspective, generic drugs and original drugs are basically the same in terms of active ingredients and bioequivalence, and their mechanism of action is also to inhibit thePI3Kα signaling pathway to block the metabolic activity of tumor cells. Generic drugs in some countries have been certified by WHO or local drug regulatory authorities to ensure drug purity and safety. However, patients should still carefully evaluate the source of drugs before use and avoid purchasing through informal channels to prevent the risk of counterfeit drugs.

In terms of therapeutic effects, there are currently no sufficient large-scale comparative studies showing significant differences in efficacy between generic drugs and original drugs. However, due to differences in production standards and excipients in different regions, some patients may have slight differences in tolerance or absorption rate. Therefore, doctors generally recommend using original drugs first during initial treatment or when the condition is more complex, and then consider generic drugs during the long-term maintenance phase or when the financial burden is heavy.

Reference materials:https://www.piqray.com/